Background. Dengue is a mosquito-borne flavivirus infection prevalent in tropical and subtropical regions around the world. Aim of this study was to determine seroprevalence of anti-dengue IgG antibodies in healthy adult population of Lahore and also describe risk factors in relation to dengue seropositivity. Methods. In this cross-sectional study, 274 healthy adult individuals aged 15 years and above were randomly selected using multistage sampling technique. These individuals were interviewed between July–September 2012, using a semistructured questionnaire, followed by drawing 3？mL of their venous blood for dengue IgG test. Nova Tech ELISA kit with sensitivity and specificity of 96.5% and 97.5%, respectively, was used for serology. Results. Out of 274 participants, 184 (67.2%) were found to be positive for dengue IgG antibodies. Seroprevalence was higher among individuals with poor awareness about potential breeding sites for dengue mosquito (63.6%), followed by the subjects who had poor knowledge about dengue signs/symptoms and complications (52.2% and 68.5%, resp.). Conclusion. About two-third of healthy population of Lahore was also seropositive for anti-dengue IgG during July–September 2012, indicating a considerable burden of subclinical dengue infection in the city. Males were predominantly affected than the females. We found no statistical association between dengue IgG seropositivity and socioeconomic status, occupation, and knowledge about the disease. 1. Background Dengue is a mosquito-borne flavivirus infection prevalent in tropical and subtropical regions around the world, and it has emerged as an important global public health challenge. In recent years, disease transmission has increased predominantly in urban and semiurban areas owing to economic reasons and migration. There are four distinct but closely related serotypes (DEN-1, DEN-2, DEN-3, and DEN-4) of the dengue virus known; however, DEN-2 infection is more prevalent in South Asian region including Pakistan [1, 2]. Recovery from one type of virus infection, though, provides lifelong immunity against that particular serotype, but there is a strong evidence suggesting the occurrence of severe clinical manifestations of dengue fever in subsequent infection from other serotypes [3]. Infective female Aedes aegypti mosquito species is the primary vector for dengue which transmits the virus through biting humans. On the other hand, Aedes albopictus is responsible for maintaining the endemicity in the population [4]. Absence of an effective vaccine, vector control measures, and personal
References
[1]
T. Yamashiro, M. Disla, A. Petit et al., “Seroprevalence of IgG specific for dengue virus among adults and children in Santo Domingo, Dominican Republic,” American Journal of Tropical Medicine and Hygiene, vol. 71, no. 2, pp. 138–143, 2004.
[2]
W. J. H. McBride and H. Bielefeldt-Ohmann, “Dengue viral infections; pathogenesis and epidemiology,” Microbes and Infection, vol. 2, no. 9, pp. 1041–1050, 2000.
[3]
S. Junglen, A. Kopp, A. Kurth, G. Pauli, H. Ellerbrok, and F. H. Leendertz, “A new flavivirus and a new vector: characterization of a novel flavivirus isolated from Uranotaenia mosquitoes from a tropical rain forest,” Journal of Virology, vol. 83, no. 9, pp. 4462–4468, 2009.
[4]
E. Huhtamo, N. Putkuri, S. Kurkela et al., “Characterization of a novel flavivirus from mosquitoes in Northern Europe that is related to mosquito-borne flaviviruses of the tropics,” Journal of Virology, vol. 83, no. 18, pp. 9532–9540, 2009.
[5]
D. J. Gubler, “Dengue and dengue hemorrhagic fever,” Clinical Microbiology Reviews, vol. 11, no. 3, pp. 480–496, 1998.
[6]
M. Malik, “Dengue prevention, control and management,” in Proceedings of the WHO Collaborated International Conference, Lahore, Pakistan, 2012.
[7]
World Health Organization, Dengue and Severe Dengue, WHO Media Centre, 2012.
[8]
R. V. Gibbons and D. W. Vaughn, “Dengue: an escalating problem,” British Medical Journal, vol. 324, no. 7353, pp. 1563–1566, 2002.
[9]
E. Descloux, M. Mangeas, C. E. Menkes et al., “Climate-based models for understanding and forecasting dengue epidemics,” PLoS Neglected Tropical Diseases, vol. 6, no. 2, Article ID e1470, 2012.
[10]
Y. Higa, “Dengue vectors and their spatial distribution,” Tropical Medicine and Health, vol. 39, no. 4, pp. 17–27, 2011.
[11]
S. B. Halstead, “Dengue,” The Lancet, vol. 370, no. 9599, pp. 1644–1652, 2007.
[12]
N. Sultana, S. K. Biswas, T. Sultan, S. Ahmed, Z. Hossein, and R. Chaowdhry, “Seroprevalence of dengue fever in Chittagong, Bangladesh,” Chattagram Maa-O-Shishu Hospital Medical College Journal, vol. 12, no. 1, pp. 38–40, 2013.
[13]
S. B. Halstead, “Pathogenisis of dengue: challenges to molecular biology,” Science, vol. 239, no. 4839, pp. 476–481, 1988.
[14]
P. M. Ukey, S. A. Bondade, P. V. Paunipagar, R. M. Powar, and S. L. Akulwar, “Study of seroprevalence of dengue fever in central India,” Indian Journal of Community Medicine, vol. 35, no. 4, pp. 517–519, 2010.
[15]
H. Zafar, M. Dhodhy, A. Hayyat, N. Akhtar, F. Rizwan, and B. Chaudhary, “Seroprevalence of dengue viral infection in healthy population residing in Rural Areas of District Rawalpindi,” International Journal of Pathology, vol. 8, no. 1, pp. 13–15, 2010.
[16]
G. N. Malavige, S. Fernando, J. Aaskov et al., “Seroprevalence of anti-dengue virus antibodies in children in Colombo district, Sri Lanka,” Dengue Bulletin, vol. 30, pp. 68–71, 2006.
[17]
J. Duncombe, P. Weinstein, J. Aaskov, M. Rouke, and R. Grant, “Seroprevalence of dengue in American Samoa, 2010,” Emerging Infectious Diseases, vol. 19, no. 2, pp. 324–326, 2013.
[18]
A. Amarasinghe, J. N. Kuritsky, G. William Letson, and H. S. Margolis, “Dengue virus infection in Africa,” Emerging Infectious Diseases, vol. 17, no. 8, pp. 1349–1354, 2011.
[19]
C. Braga, C. F. Luna, C. M. T. Martelli et al., “Seroprevalence and risk factors for dengue infection in socio-economically distinct areas of Recife, Brazil,” Acta Tropica, vol. 113, no. 3, pp. 234–240, 2010.
